CompletedPhase 1

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Japan4 participantsStarted 2021-03-22

Plain-language summary

The purpose of this study is to confirm the safety and tolerability of elranatamab (PF-06863135) in Japanese participants with relapsed or refractory MM.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Serum myeloma (M) protein ≥0.5 g/dL (5 g/L)
✓. Urine M protein ≥200 mg/24 h
✓. Serum free light chain (FLC) \>100 mg/L (10 mg/dL) with abnormal kappa:lambda ratio

What they're measuring

Number of Participants With Dose Limiting Toxicities (DLTs)

Timeframe: Up to 4 weeks

Trial details

NCT IDNCT04798586

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-05-27

Results submitted2023-05-25

View on ClinicalTrials.gov More Relapsed or Refractory Multiple Myeloma trials